Phyllis Yale - DaVita HealthCare Independent Director
| DVA Stock | USD 149.01 0.00 0.00% |
Director
Ms. Phyllis R. Yale is Independent Director of the Company. She was one of our directors since July 2016. Ms. Yale was an Advisory Partner with Bain Company, Inc., a global management consulting firm, since July 2010. Ms. Yale was a partner with Bain from 1987 to July 2010, and was a leader in building Bains healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the worlds leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and currently serves as Chair of the board of directors of Blue Cross Blue Shield of Massachusetts, a notforprofit health plan headquartered in Boston. Ms. Yale previously served as Chair of the board of directors of Kindred Healthcare, Inc., a provider of longterm healthcare services in the United States, from January 2010 until July 2018, a director of National Surgical Hospitals, a privately held specialty hospital operator, and a director of ValueOptions, Inc., a health improvement company specializing in mental and emotional wellbeing and recovery, which merged with Beacon Health Strategies during 2014 since 2016.
| Age | 62 |
| Tenure | 9 years |
| Address | 2000 16th Street, Denver, CO, United States, 80202 |
| Phone | 720-631-2100 |
| Web | https://www.davita.com |
Phyllis Yale Latest Insider Activity
Tracking and analyzing the buying and selling activities of Phyllis Yale against DaVita HealthCare stock is an integral part of due diligence when investing in DaVita HealthCare. Phyllis Yale insider activity provides valuable insight into whether DaVita HealthCare is net buyers or sellers over its current business cycle. Note, DaVita HealthCare insiders must abide by specific rules, including filing SEC forms every time they buy or sell DaVita HealthCare'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Phyllis Yale over three months ago Disposition of 3500 shares by Phyllis Yale of DaVita HealthCare subject to Rule 16b-3 | ||
Phyllis Yale over a year ago Acquisition by Phyllis Yale of 581 shares of Bristol Myers subject to Rule 16b-3 |
DaVita HealthCare Management Efficiency
The company has Return on Asset of 0.0715 % which means that on every $100 spent on assets, it made $0.0715 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.5174 %, implying that it generated $0.5174 on every 100 dollars invested. DaVita HealthCare's management efficiency ratios could be used to measure how well DaVita HealthCare manages its routine affairs as well as how well it operates its assets and liabilities. At present, DaVita HealthCare's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Equity is expected to grow to 8.12, whereas Return On Tangible Assets are forecasted to decline to 0.07. At present, DaVita HealthCare's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 247.1 M, whereas Total Assets are forecasted to decline to about 10.5 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Christopher Reidy | Encompass Health Corp | 64 | |
| Lloyd Austin | Tenet Healthcare | 65 | |
| Mark Foletta | AMN Healthcare Services | 60 | |
| Eileen McDonnell | Universal Health Services | 57 | |
| Charles Elson | Encompass Health Corp | 60 | |
| William Frist | HCA Holdings | 51 | |
| Michael Johns | AMN Healthcare Services | 78 | |
| Maria Singer | Universal Health Services | 46 | |
| Ross Comeaux | Community Health Systems | N/A | |
| James Bierman | Tenet Healthcare | 68 | |
| Wayne Riley | HCA Holdings | 61 | |
| NancyAnn DeParle | HCA Holdings | 64 | |
| Tammy Romo | Tenet Healthcare | 58 | |
| J Kerrey | Tenet Healthcare | 77 | |
| Richard Mark | Tenet Healthcare | 65 | |
| James Ely | Community Health Systems | 63 | |
| Elliot Sussman | Universal Health Services | 68 | |
| Leslye Katz | Encompass Health Corp | 66 | |
| John Maupin | Encompass Health Corp | 73 | |
| William Jennings | Community Health Systems | 77 | |
| Julia North | Community Health Systems | 72 | |
Management Performance
| Return On Equity | 0.52 | ||||
| Return On Asset | 0.0715 |
DaVita HealthCare Leadership Team
Elected by the shareholders, the DaVita HealthCare's board of directors comprises two types of representatives: DaVita HealthCare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DaVita. The board's role is to monitor DaVita HealthCare's management team and ensure that shareholders' interests are well served. DaVita HealthCare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DaVita HealthCare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Hearty, Chief Compliance Officer | ||
| Shawn Guertin, Director | ||
| Javier Rodriguez, Chief Executive Officer, Director | ||
| Paula Price, Independent Director | ||
| Paul Diaz, Independent Director | ||
| Misha Palecek, Chief Business | ||
| Christopher Berry, Group Officer | ||
| Christopher CPA, Group Officer | ||
| Jeffrey Giullian, Chief Care | ||
| John Nehra, Independent Director | ||
| Phyllis Yale, Independent Director | ||
| BSN MBA, Chief Officer | ||
| Madhu Narasimhan, Chief Officer | ||
| Mandy Hale, Chief Officer | ||
| Jim Gustafson, Vice President - Investor Relations | ||
| John Winstel, Chief Accounting Officer, Group Vice President | ||
| Kenneth Smith, Chief Officer | ||
| Jessica Hergenreter, Chief Officer | ||
| Gregory Moore, Independent Director | ||
| David Roer, Chief Medical Officer - DaVita Integrated Kidney Care | ||
| FRCPC MD, Chief Operations | ||
| Nic Eliason, Group Relations | ||
| Atul Mathur, Executive Vice President of Global Operations | ||
| Joel Ackerman, Chief Financial Officer, Treasurer | ||
| Kathleen Waters, Chief Legal and Public Affairs Officer | ||
| Pamela Arway, Independent Chairman of the Board | ||
| Michael Staffieri, Chief Operating Officer- DaVita Kidney Care | ||
| Pascal Desroches, Independent Director | ||
| David Maughan, Chief Officer | ||
| LeAnne Zumwalt, Group Vice President - purchasing and government affairs | ||
| Kenny Gardner, Chief People Officer - DaVita Kidney Care | ||
| Barbara Desoer, Independent Director | ||
| Mihran Naljayan, Chief Medical Officer - Home Modalities | ||
| Charles Berg, Independent Director | ||
| MSc MD, Chief International |
DaVita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DaVita HealthCare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.52 | ||||
| Return On Asset | 0.0715 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 23.21 B | ||||
| Shares Outstanding | 80 M | ||||
| Shares Owned By Insiders | 48.62 % | ||||
| Shares Owned By Institutions | 49.82 % | ||||
| Number Of Shares Shorted | 4.56 M | ||||
| Price To Earning | 11.43 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DaVita HealthCare offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DaVita HealthCare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Davita Healthcare Partners Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Davita Healthcare Partners Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DaVita HealthCare Partners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DaVita HealthCare. If investors know DaVita will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DaVita HealthCare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.909 | Earnings Share 10.72 | Revenue Per Share | Quarterly Revenue Growth 0.047 | Return On Assets |
The market value of DaVita HealthCare is measured differently than its book value, which is the value of DaVita that is recorded on the company's balance sheet. Investors also form their own opinion of DaVita HealthCare's value that differs from its market value or its book value, called intrinsic value, which is DaVita HealthCare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DaVita HealthCare's market value can be influenced by many factors that don't directly affect DaVita HealthCare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DaVita HealthCare's value and its price as these two are different measures arrived at by different means. Investors typically determine if DaVita HealthCare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DaVita HealthCare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.